HIGHLIGHTS
- who: Daniel E. Lefever and colleagues from the Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, USA have published the research: A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies, in the Journal: (JOURNAL)
- what: This analysis has enabled the authors to associate distinct clusters of individual patient gene_expression and pathway enrichment profiles with three NAFLD sub-classifications: predominantly normal and steatosis (PN and amp;S); predominantly lobular inflammation (PLI), typical of NASH early stages; and predominantly fibrosis (PF . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.